Jamieson Wellness Inc. Announces Filing of Management Information Circular for Annual Meeting of Shareholders Life Science Investing
 Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older Life Science Investing
AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology 2022 Annual Meeting Pharmaceutical Investing
European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer Pharmaceutical Investing
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential Life Science Investing
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere Pharmaceutical Investing
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis Pharmaceutical Investing
AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH Pharmaceutical Investing
Knight Therapeutics Inc. places on The Globe and Mail's third-annual Women Lead Here benchmark of executive gender diversity Pharmaceutical Investing
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® for Patients With Microsatellite Instability-High or Mismatch Repair Deficient Tumors in Five Different Types of Cancer Life Science Investing
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 Life Science Investing
